New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
16:25 EDTSAM, S, AZN, ZAGG, CLWR, RIGL, BBYOn The Fly: Closing Wrap
Stocks on Wall Street finished lower but off their worst levels amid more political gamesmanship over the fiscal cliff. Both House Speaker John Boehner and Senate Majority Leader Harry Reid made comments regarding the increasing gridlock in negotiations, sending the averages lower just before midday. The averages touched their lows around 2:00 pm, but rallied in the last half hour of trading after reports that the President would meet with Speaker Boehner this evening for further cliff talks... ECONOMIC EVENTS: In the U.S., weekly jobless claims fell 29,000 to 343,000, versus expectations for a drop to 369,000. Producer prices in the month of November fell 0.8%, versus an expected decline of 0.5%. "Core" prices, excluding food and energy, rose 0.1%, which matched expectations. Retail sales rose 0.3% in November, which missed expectations for an increase of 0.5%. In Europe, the region's finance ministers approved the release of more financial aid to Greece and came to terms on a foundation for ECB oversight of a true banking union... COMPANY NEWS: Shares of Clearwire (CLWR) rose 41c, or 14.91%, to $3.16 after Sprint (S) disclosed an offer to buy the remaining stake in the company it does not already own for $2.90 per share. Clearwire said that its talks with Sprint are ongoing. Meanwhile, Sprint shares slipped fractionally, down 2c, or 0.35%, to $5.64... MAJOR MOVERS: Among the notable gainers was Best Buy (BBY), up $1.94, or 15.93%, to $14.12 after the Star Tribune said the company's founder Richard Schulz will soon make an offer for the company. Also higher were ZAGG (ZAGG), up 73c, or 10.27%, to $7.84 after the company announced a $10M share repurchase program, and Boston Beer (SAM), up $17.71, or 15.50%, to $131.94 after raising its FY12 EPS guidance. Among the noteworthy losers was Rigel Pharmaceuticals (RIGL), which fell $2.94, or 34.88%, to $5.49 after an RA drug it is developing in partnership with AstraZeneca (AZN) failed to meet one of its endpoints in a trial. Shares of AstraZeneca also traded down $1.44, or 2.94%, to $47.46... INDICES: The Dow was down 74.73, or 0.56%, to 13,170.72; the Nasdaq was down 21.65, or 0.72%, to 2,992.16; and the S&P 500 was 9.03, or 0.63%, to 1,419.45.
News For CLWR;S;BBY;ZAGG;SAM;RIGL;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2015
11:06 EDTSSprint introduces Family Share Pack plan
With more data than T-Mobile (TMUS), and with significant savings over Verizon (VZ) and AT&T (T), Sprint (S) introduces the new Sprint Family Share Pack. Families switching to Sprint get four lines, unlimited talk, text and 10GB of high-speed data while on the Sprint network for $100/month starting July 31. Sprint says its new plan will save families $480/year over Verizon and $720/year over AT&T for virtually the same 10GB of data. Sprint says that 10GB is more than double the high-speed data in T-Mobile’s family plan.
10:41 EDTBBYOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTBBYOptions with decreasing implied volatility
Subscribe for More Information
July 28, 2015
07:20 EDTAZNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
06:05 EDTBBYBest Buy to begin selling Apple Watch in August, WSJ reports
Subscribe for More Information
05:25 EDTAZNGenzyme acquires Caprelsa from AstraZeneca for $300M
Genzyme, a Sanofi (SNY) company, announced that it has entered into a definitive agreement with AstraZeneca (AZN) to acquire Caprelsa, a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa is an oral kinase inhibitor treatment and is currently available in 28 countries. Caprelsa is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300M, including an upfront payment of $165M to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135M. The transaction does not include the transfer of any AstraZeneca employees or facilities.
July 23, 2015
19:24 EDTBBYWal-Mart's Apple Pay competitor launching soon, Bloomberg says
CurrentC, the mobile payment application funded by Wal-Mart (WMT), Target (TGT), Best Buy (BBY) and others, will see an early trial run next month, Bloomberg reported earlier, citing three people familiar with the situation. A spokesperson for Lowe's (LOW) said the consortium behind the app expects an official launch in Q3, and Bloomberg noted that CurrentC will compete with more "established" offerings such as Apple's (AAPL) Apple Pay and Google's (GOOG) Android Pay. Reference Link
07:22 EDTSSprint price target lowered to $3 from $4 at Jefferies
Subscribe for More Information
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
July 20, 2015
09:31 EDTBBYBest Buy store rationalization to be catalyst, says BB&T
Subscribe for More Information
July 17, 2015
16:24 EDTBBYOn The Fly: Top stock stories for Friday
Subscribe for More Information
12:38 EDTBBYOn The Fly: Top stock stories at midday
Subscribe for More Information
10:46 EDTBBYBest Buy sinks after analyst says sell to avoid comp sales risk
Subscribe for More Information
10:13 EDTBBYAmbarella to get boost from drone demand, analyst says
Ambarella (AMBA) should benefit from stronger than expected demand for drones, which are "literally flying off the shelves" at Best Buy (BBY), research firm Pacific Crest wrote in a note to investors today. Ambarella develops processors used in high definition cameras, such as those often utilized by drones. WHAT'S NEW: After conducting checks, Pacific Crest analyst Brad Erickson wrote that sales of drones have been stronger than expected. Ambarella should benefit from that trend, as well as from the fact that demand for GoPro (GPRO) cameras, which utilize Ambarella's chips, has been steady, Erickson stated. Although initial demand for GoPro's new Session camera "appears lukewarm," its newer cameras should drive a significant increase in sales volume starting in GoPro's October quarter, according to Erickson, who said the popularity of GoPro's cameras should enable Ambarella's results to beat Street expectations. The analyst continues to recommend buying Ambarella's stock and kept a $123 price target on the shares. WHAT'S NOTABLE: In a note to investors yesterday, Piper Jaffray analyst Erinn Murphy wrote that GoPro's risk/reward ratio was favorable heading into the company's Q2 results. According to Murphy, the stock fell recently because money rotated out of the shares following the initial public offering of Fitbit (FIT) and Goldman Sachs' initiation of coverage of the stock with a Neutral rating. However, Amazon (AMZN) data shows that GoPro's cameras are selling well and Ambarella's Q2 results beat expectations, Murphy noted. As a result, she expects GoPro's Q2 results to exceed expectations when they are reported next week. Murphy reiterated a $68 price target and Overweight rating on GoPro shares. PRICE ACTION: In early trading, Ambarella rose 1.3% to $109.59, while GoPro added 0.5% to $55.53.
10:05 EDTBBYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Accretive Health (ACHI) downgraded to Market Perform from Outperform at Cowen... Allergan (AGN) downgraded to Outperform from Top Pick at RBC Capital... Best Buy (BBY) downgraded to Underperform from Buy at BofA/Merrill... Cablevision (CVC) downgraded to Hold from Buy at Jefferies... Credit Suisse (CS) downgraded to Hold from Buy at Deutsche Bank... Domino's Pizza (DPZ) downgraded to Sector Weight from Overweight at KeyBanc... First Quantum Minerals (FQVLF) downgraded to Neutral from Outperform at Credit Suisse... First Republic (FRC) downgraded to Market Perform from Outperform at FBR Capital... Fresenius SE (FSNUY) downgraded to Neutral from Buy at Goldman... Golden Minerals (AUMN) downgraded to Neutral from Buy at Roth Capital... JD Wetherspoon (JDWPY) downgraded to Reduce from Neutral at Nomura... NV5 Holdings (NVEE) downgraded to Neutral from Accumulate at Global Hunter... National Oilwell (NOV) downgraded to Sell from Neutral at UBS... Natural Gas Services (NGS) downgraded to Neutral from Buy at Global Hunter... Primoris (PRIM) downgraded to Neutral from Accumulate at Global Hunter... Receptos (RCPT) downgraded to Hold from Buy at Evercore ISI... SKF AB (SKFRY) downgraded to Hold from Buy at Deutsche Bank... STAG Industrial (STAG) downgraded to Sell from Neutral at UBS... SolarWinds (SWI) downgraded to Hold from Buy at Deutsche Bank... Syntel (SYNT) downgraded to Market Perform from Outperform at William Blair... TECO Energy (TE) downgraded to Neutral from Buy at UBS... Tangoe (TNGO) downgraded to Underweight from Equal Weight at Barclays... Tegna (TGNA) downgraded to Hold from Buy at Evercore ISI.
09:44 EDTBBYBest Buy falls after downgrade, levels to watch
Shares are down over 5% to $33.08. At that price next support is at $32.56, a recent pivot low, and then at $31.78. Resistance is at $34.14. BofA/Merrill earlier downgraded the shares to Underperform and cut its price target to $32.
07:26 EDTBBYBofA/Merrill downgrades Best Buy two notches to Underperform
As previously reported, BofA/Merrill downgraded Best Buy to Underperform from Buy. The firm lowered estimates based on limited catalysts and continued investments and warned that a mixed product cycle could result in 2H comp downside. BofA/Merrill believes the consensus estimate of 1% comps for 2H look challenging given ongoing computer weakness, ongoing tablet commodization and pricing pressure and flat mobile trends. The firm cut its price target on Best Buy to $32 from $45.
07:07 EDTBBYBest Buy downgraded to Underperform from Buy at BofA/Merrill
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use